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Cyclooxygenase-2 Overexpression in Human Basal
Cell Carcinoma Cell Line Increases Antiapoptosis,
Angiogenesis, and Tumorigenesis
Jeng-Wei Tjiu1,4, Yi-Hua Liao1,4, Sung-Jan Lin1, Yi-Ling Huang1, Wei-Ling Tsai1, Chia-Yu Chu1,2,
Min-Liang Kuo2 and Shiou-Hwa Jee1,3
Cyclooxygenase-2 (COX-2) is critical for tumor formation, angiogenesis, metastasis, and prognosis. In this study,
the role of COX-2 in antiapoptosis, tumorigenesis, and angiogenesis of human basal cell carcinoma (BCC) cells
was investigated. Transfection of COX-2 constitutive expression vector into a BCC cell line yielded several
overexpressing clones. All transfectants demonstrated remarkable resistance to ultraviolet B-induced apoptosis
(confirmed by flow cytometry analysis, morphological change, and DNA fragmentation). Immunoblot analysis
revealed marked increases in apoptosis-regulated genes Mcl-1 and Bcl-2. A 10-fold concentrated conditioned
medium from COX-2-overexpressing BCC cells exhibited higher angiogenic activity in Matrigel plug and human
umbilical vein endothelial cell tube formation assay. Cells exhibited increased levels of vascular endothelial
growth factor-A (VEGF-A) mRNA and protein, and secreted VEGF-A and basic fibroblast growth factor (bFGF).
COX-2-specific small interfering RNA markedly reduced the secreted species. After 7 weeks of inoculation, the
tumor volume of COX-2-overexpressing cells in severe combined immunodeficient mice was significantly
greater than that of vector control cells. Immunohistochemical analysis of CD31-positive vessels revealed a two-
fold increase in microvessel density in COX-2 tumors, compared to control vector tumors. Our data indicate
that Mcl-1 and Bcl-2, as well as VEGF-A and bFGF, are downstream effectors of COX-2-induced antiapoptosis and
angiogenesis, respectively.
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INTRODUCTION
Cyclooxygenase (COX) is the key enzyme that mediates the
production of prostaglandins from arachidonic acid. So far,
two COX isoforms (cyclooxygenase-1 (COX-1) and cyclo-
oxygenase-1 (COX-2)) have been identified. COX-1 is
expressed constitutively, whereas COX-2 is induced by
growth factors, tumor promoters, and cytokines (Taketo,
1998). To date, COX-2 has been determined to contribute to
tumorigenesis and the malignant phenotype of tumor cells via
the inhibition of apoptosis, increased angiogenesis and
invasiveness, and modulation of inflammation and immuno-
suppression (Dempke et al., 2001).
Ultraviolet B (UVB, wavelength 290–320 nm) irradiation is
a major etiologic factor in the pathogenesis of non-melanotic
skin cancers, including squamous cell carcinoma and basal
cell carcinoma (BCC) (de Gruijl et al., 2001). More than one
million new non-melanotic skin cancers occur in the United
States annually, with the majority of them comprising BCC
(Miller and Weinstock, 1994). COX-2 and prostaglandin E2
(PGE2) expressions in human skin are increased after UVB
irradiation, especially in aged skin (Seo et al., 2003). Cultured
human keratinocytes display increased COX-2 protein level
and PGE2 excretion after UVB irradiation (Muller-Decker
et al., 1995; Buckman et al., 1998). Experimentally, increases
in COX-2 expression and proliferation of basal layer
keratinocytes have been demonstrated in Skh-1 hairless mice
after UVB irradiation (Fischer et al., 1999). Reductions in
UVB-induced skin papilloma or carcinoma occur upon
feeding the mice with celecoxib (a selective COX-2 inhibitor)
or indomethacin. Topical application of celecoxib also
inhibits chronic inflammation and UVB-induced papilloma/
carcinoma in Skh/hr hairless mice (Wilgus et al., 2003). The
ratio of squamous cell carcinoma to papillomas increases
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markedly in the skin of COX-2-overexpressing transgenic
mice treated with the known carcinogen 7,12-dimethyl-
benz[a]anthracene (Muller-Decker et al., 2002).
A previous immunohistochemical study described BCC to
be COX-2 negative (Vogt et al., 2001). Several other
published reports show BCC to be COX-2 positive in a low
percentage of tested biopsies (Muller-Decker et al., 1999;
Kagoura et al., 2001; Akita et al., 2004). However, a recent
publication by O’Grady et al. (2004) demonstrated that COX-
2 expression level correlated with angiogenesis in BCC
specimens taken from renal transplant recipients and
immunocompetent patients. Genetic and pharmacological
evidence suggests that overexpression of COX-2 is critical for
epithelial carcinogenesis. The purpose of the present study,
therefore, was to investigate the effects of COX-2 over-
expression on BCC cell apoptotic regulation, tumorigenesis,
and angiogenesis. The cell regulators involved in apoptosis
and angiogenesis were subsequently examined.
RESULTS
COX-2 overexpression induces resistance to apoptosis in human
BCC cell line
The human COX-2 constitutive expression plasmid pCMV-
COX-2 and the control vector pcDNA were transfected into
human BCC cell line cells, which have a relatively low level
of COX-2. After transfection, cells were cultured in a medium
containing 100 mg/ml neomycin. Four stable clones (desig-
nated as B4, C5, E4, and G7) were selected, based on their
increased expression of COX-2 mRNA and protein compared
with the vector control cells (Figure 1a and b). Elevated levels
of PGE2 production were found in clones B4 and G7, which
expressed the highest levels of COX-2 (Figure 1c).
Several apoptosis assays were performed to investigate
whether COX-2 overexpression confers antiapoptotic ability
to the human BCC cell line. A sensitive ELISA that measures
cytoplasmic histone-associated DNA fragments further con-
firmed that pcDNA clone (vector control) had a higher rate of
apoptosis than COX-2-overexpressing clones (B4 and G7) at
12 hours after UVB irradiation. Enrichment factors were
12.2770.32, 4.6770.43, and 4.2070.73 (expressed as
mean7SD) for pcDNA, B4, and G7, respectively (Po0.005
for B4 vs pcDNA and Po0.005 for G7 vs pcDNA) (Figure 2a).
There was no significant variation in enrichment factors
among pcDNA clone and COX-2-overexpressing clones (B4,
G7) at 6 hours. Flow cytometric analysis also showed a
significantly higher percentage of apoptotic cells in pcDNA
than COX-2-overexpressing clones (pcDNA vs B4, Po0.001;
pcDNA vs G7, Po0.05) (Figure 2b). Apoptotic cells were
distinguished by staining with Hoechst 33258 fluorescent
dye, which discerns chromatin condensation and nuclear
segmentation, as an additional apoptosis assessment. As
shown in Figure 2c, B4 and G7 cells had fewer apoptotic
cells than the vector control cells when exposed to UVB
irradiation.
The expression levels of the Bcl-2 family proteins were
examined to identify possible downstream genes regulated by
COX-2. Figure 3 reveals that the level of Mcl-1 protein was
increased three- to four-fold in COX-2-overexpressing stable
clones as compared with the vector control clone, and
the level of Bcl-2 protein increased by 1.8- to 2.6-fold in
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Figure 1. Determination of COX-2 mRNA, protein, and secreted PGE2 levels
in COX-2-transfected BCC cells. (a) The mRNA of various cell lines as
indicated was extracted and semiquantified by reverse transcriptase-PCR of
COX-2. (b) The protein extracted from cell lysates was quantified by Western
blotting for COX-2. (a, b) The number below each lane indicates the relative
densitometric intensity to control (defined as 1.0). This represents one of three
experiments. (c) The secretion of PGE2 in culture supernatant was measured
by ELISA. Concentration of PGE2 was expressed as mean7SD in five
experiments. Student’s t-test was used for comparison. pcDNA: vector
control; B4, C5, E4, and G7: clones of COX-2 transfectants.
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Figure 2. Expression of COX-2 protects BCC cells against apoptosis. (a) The
cell apoptosis was measured by cell death ELISA. Enrichment factor (EF) was
defined as mU of sample (12 hours after UVB irradiation)/mU of the negative
control (without UVB irradiation) (mU¼ absorbance (103)). (b) Flow
cytometric analysis with propidium iodide staining. (c) Nuclear fragmentation
and chromatin condensation (arrow) determined by staining with Hoechst
33258 fluorescent dye. Each cell line was treated with 25 mJ/cm2 UVB, and
harvested at 12 hours (a) and at 24 hours (b, c). Data are expressed as
mean7SD in (a, b). (c) One of three reproducible experiments. Student’s
t-test was used for comparison (n¼3). pcDNA: vector control; B4 and
G7: COX-2-overexpressing BCC clones. Bar¼10 mm.
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COX-2-expressing clones. In contrast, the levels of the other
Bcl-2 family members phospho-BAD and Bcl-XL were not
significantly affected in COX-2 stable clones.
COX-2 overexpression increases angiogenesis both in vitro and
in vivo
The effect of COX-2 on angiogenesis in vitro was initially
examined by tube formation of human umbilical vein
endothelial cells (HUVECs) cultured with conditioned med-
ium (CM). Formation of the network-like tubular HUVEC
structure involves the migration, invasion, and differentiation
of endothelial cells. The CM obtained from the COX-2-
overexpressing clones B4 and G7 showed increased tube
formation per microscopic field as compared to controls
(10.471.78, Po0.0005 for B4 and 10.271.78, Po0.0005
for G7 clone vs 0 for the vector control) (Figure 4a and b).
The effect of COX-2 on the induction of angiogenesis was
assessed in vivo using the Matrigel plug assay. Upon visual
examination, substantial vasculature was evident in plugs
embedded with CM from COX-2-overexpressing BCC cells,
even with hemorrhaging in the plugs, as compared to vector
controls (Figure 4c). The B4 and G7 clones showed
significant increases in hemoglobin relative to the control
(4.5571.7 mg hemoglobin/mouse for B4, 4.3272.5 mg
hemoglobin/mouse for G7 vs 0.2270.16 hemoglobin mg/
mouse for control) (both Po0.05) (Figure 4d).
The observation that COX-2 induced angiogenesis in mice
prompted the study of COX-2-transfected BCC cells to
determine their expression of angiogenic factors. Reverse
transcriptase-PCR and immunoblotting were employed to
analyze the expression of angiogenic factors including IL-8,
vascular endothelial growth factor-A (VEGF-A), basic fibro-
blast growth factor (bFGF), and platelet-derived growth
factor. As shown in Figure 5a, the expression of VEGF-A
mRNA in COX-2-transfected BCC cells was higher than in
vector control cells. The expression of IL-8 mRNA was also
slightly increased in COX-2-overexpressing clones (varying
from 1.1- to 1.6-fold). Immunoblotting analysis showed that
COX-2-overexpressing BCC cells expressed more abundant
VEGF-A than vector controls (Figure 5b). Secreted levels of
VEGF-A and bFGF were also increased significantly in B4 and
G7 clones in comparison with vector control or parent BCC
cells (Po0.0001) (Figure 5c).
A loss-of-function assay was performed by blocking COX-2
function using COX-2-specific siRNA. Protein levels of
COX-2 reduced by 51.7% and secreted PGE2 decreased by
57.38 % in COX-2-overexpressing clones transiently trans-
fected with COX-2-specific siRNA, which confirmed the
knockdown effect of RNA interference (data not shown). The
B4 and G7 clones showed statistically significant decreases in
both secreted VEGF-A (54 and 56.8%, respectively) and
bFGF (74 and 47.5%, respectively) after being transiently
transfected with COX-2-specific siRNA (Figure 5d).
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Figure 3. Immunoblot analysis of Mcl-1, Bcl-2, Bcl-XL, and phosphor-BAD
proteins in different COX-2-expressing cell lines. Cell lysates were prepared
and immunoblotting was performed as described in Materials and Methods.
Equal aliquots of protein extracted from pcDNA, B4, C5, E4, and G7 clones
were electrophoresed, and the proteins were transferred to a nitrocellulose
support. The nitrocellulose was probed with specific antibodies as indicated.
The number below each line indicates the relative densitometric density to
control (defined as 1.0). This represents one of three reproducible experi-
ments. pcDNA: vector control; B4, C5, E4, and G7: COX-2-overexpressing
BCC clones.
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Figure 4. COX-2 overexpression increases angiogenesis both in vivo and in
vitro. (a) Ten times concentrated culture supernatants (CM) collected from
COX-2 transfectants and vector control incubated with HUVECs as depicted.
(b) The number of tube-like structures was expressed as the mean7SD
following a random count of five 9.7 mm2 microscopic fields. (c) CM from the
COX-2-overexpressing clones and vector control were used for Matrigel
blood plug assay in C57BL6j mice (five per group). The mice were killed 7
days after implantation. Gross appearance of the plugs was photographed.
(d) The blood plugs were extracted and quantitation of hemoglobin was
performed using the Drabkin method. The mean amount of hemoglobin was
calculated. Student’s t-test was used for comparison. Bar¼ 100mm.
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The COX-2-specific inhibitor NS-398 was also used to
demonstrate specificity of the COX-2 transfection effects, and
the secreted levels of PGE2 were decreased by 90.3% in B4
clone and by 91.1% in G7 clone after 25 mM NS-398
treatment for 24 hours (data not shown). The B4 and G7
clones showed significant decreases in the secreted levels of
VEGF-A (59.0 and 68.%, respectively) and bFGF (86.3 and
81.8%, respectively) after treatment with 25 mM NS-398 for
24 hours (Figure 5e).
Increased tumor growth and tumor angiogenesis in BCC cells
with COX-2 overexpression in SCID mice
To compare the cell transformation ability of COX-2
transfectants and vector control cells, we employed a soft
agar growth assay. A total of 1103 cells from pcDNA, B4,
and G7 clones were seeded into soft agar plate and colony
numbers were counted 28 days after seeding. The results
showed 9.272.0, 24.773.7, and 25.875.4 colonies in a
high-power field ( 200) for pcDNA, B4, and G7 respec-
tively (B4 vs pcDNA, Po0.001; G7 vs pcDNA, Po0.001)
(Figure 6a). Microscopic examination also revealed that both
B4 and G7 clones showed colonies much larger than those of
the pcNDA clone (Figure 6b).
Tumorigenicity of COX-2-overexpressing clones and
vector control cells in severe combined immunodeficient
(SCID) mice model was next explored. Cells from pcDNA,
B4, and G7 (5106 each) were subcutaneously injected into
5-week-old SCID mice. The mean tumor size in G7-
transplanted SCID mice was approximately 6,833 mm3 on
day 47. The B4 xenograft reached a mean of 4,377 mm3 on
day 47. In contrast, the mean tumor volume in SCID mice
injected with pcDNA cells reached only a mean of
1,821 mm3 by the same day (P¼0.0097) (Figure 7a and b).
The xenograft volume reached a statistically significant
difference 22 days after implantation (P¼0.0231). Immuno-
histochemical analysis of xenograft resection specimens
confirmed that COX-2 staining was higher in COX-2-
overexpressing clones (data not shown).
The number of blood vessels in COX-2-overexpressing
xenograft tumors was quantified. A correlation was evident
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Figure 5. Expression of angiogenic factors in COX-2-transfected BCC cells. (a) Reverse transcriptase-PCR analysis of the level of VEGF-A, bFGF, platelet-
derived growth factor, and IL-8 mRNA in COX-2 transfectants (B4, C5, E4, and G7) and vector control (pcDNA) cells. (b) Western blot analysis of VEGF-A
protein in COX-2-overexpressing and vector control BCC cells. (c–e) Changes of secreted VEGF-A and bFGF were measured by ELISA. Concentrations of VEGF-A
and bFGF were expressed as the mean7SD of three independent experiments. Student’s t-test was used for statistical analysis (c–e). Different culture conditions
were used. (c) A total of 2 105 cells of BCC, pcDNA, B4, and G7 clones were seeded in 1.6 cm diameter culture plates, and the supernatants were collected at
48 hours. (d) A total of 3105 cells of B4 and G7 clones were seeded in 10 cm diameter culture dishes and transiently transfected with COX-2-specific siRNA.
Culture supernatants were collected at 48 hours for ELISA after siRNA transfection. (e) A total of 2 105 cells of B4 and G7 were seeded in 1.6 cm diameter
culture dishes, and cultured with 25 mM of NS-398 (COX-2-specific inhibitor). Supernatants were collected for ELISA at 24 hours after supplement of NS-398.
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between the level of expression of COX-2 and the density
of tumor microvessels (8.9672.26 vessels/microscopic
field for B4 cells, n¼5, Po0.05, 8.2271.25 vessels/micro-
scopic field for G7 cells, Po0.05, n¼5 vs 4.4670.77
vessels/microscopic field for pcDNA cells, n¼5) (Figure 8a
and b).
DISCUSSION
Accumulated evidence suggests that cancer cells expressing
higher levels of COX-2 may obtain a survival advantage that
eventually facilitates tumor development and progression
(Dannenberg et al., 2005). We have shown that IL-6
overexpression in BCC cells increases expression of COX-2
and is accompanied by high vascularization (Jee et al., 2001).
Blockage of COX-2 function by siRNA abrogates IL-6-
mediated angiogenic activities (Jee et al., 2004) in a manner
consistent with a downstream COX-2 effect of IL-6-induced
angiogenesis in BCC cells. Several reports described that BCC
had a low positive rate for COX-2 immunohistochemical
staining in tested biopsies (Muller-Decker et al., 1999;
Kagoura et al., 2001; Vogt et al., 2001; Akita et al., 2004).
But recently, O’Grady et al. (2004) showed a positive staining
of COX-2 in BCC, and demonstrated that COX-2 expression
was correlated with microvessel densities. We found that
higher levels of COX-2 expression not only associated with
neovascularization but also correlated with tumor invasion
depth in human BCC specimens (manuscript in submission).
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Figure 6. Anchorage-independent growth of COX-2-overexpressing BCC
clones. (a) Anchorage-independent growth of COX-2-transfected BCC cells.
A total of 1103 cells were mixed in 0.35% soft agar and plated in a 3.5 cm
diameter plate. Twenty eight days after seeding, the number of colonies was
determined. Results shown are the mean7SD of three experiments.
(b) Colony morphology of COX-2 overexpression clones (B4 and G7)
and vector control (pcDNA) cells. Bar¼0.2 mm.
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Figure 7. Tumorigenic effect of COX-2-overexpressing BCC cells in SCID
mice. The vector control and COX-2-overexpressing clones (B4 and G7) were
injected into SCID mice by subcutaneous inoculation of 5106 cells (four
mice per group). (a) The gross appearance of the xenograft following the
killing of SCID mice performed 7 weeks after injection of BCC cells (a) and
tumor size were assessed as described in Materials and Methods (b). Four
independent experiments were performed. Significance was assessed using
the Kruskal–Wallis equality of populations rank test.
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Figure 8. Microvessel density was increased in COX-2-overexpressing
xenografts. (a) Immunohistochemical staining of sections of xenografts using
anti-CD31 antibody. (b) Quantitative analysis of CD31-positive vessels
(mean7SD) by the standard method of microvessel density determination.
pcDNA: vector control; B4 and G7: COX-2-overexpressing BCC clones.
Bar¼50 mm.
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In the present study, we demonstrate the function of COX-
2 in tumorigenesis and angiogenesis by both molecular
dissection and in vivo inspection. COX-2 is an enzyme that
mediates many physiological functions, such as inhibition of
cell apoptosis, augmentation of angiogenesis, and increased
cell motility. The COX-2-mediated functions are influenced
in part by various genes such as VEGF-A (Ma et al., 2002),
CD44, and matrix metalloproteinases (Dohadwala et al.,
2002). High COX-2 levels in the human colon (Tsujii et al.,
1998) and gastric cancers (Jones et al., 1999) greatly promote
tumor growth by increasing microvessel density (ie angiogen-
esis). VEGF-A is a major downstream effecter gene of COX-2-
induced angiogenesis in colon cancer (Seno et al., 2002).
Recently, it was shown in Apc/COX-2 double knockout mice
that stromal expression of COX-2 is required for the induction
of VEGF and subsequent tumor angiogenesis (Seno et al.,
2002). Tumors in COX-2 knockout mice showed decreased
expression of VEGF mRNA and a 30% decrease in vascular
density compared with wild type (Williams et al., 2000). Loss
of wild-type p53, a tumor suppressor gene, is associated with
increased expression of COX-2 mRNA and increased release
of bFGF (Galy et al., 2001) and VEGF (Yuan et al., 2002). The
product of COX-2 enzymatic function, PGE2, stimulates
VEGF production by promoting the translocation of hypoxia-
inducible factor-a from cytosol to nucleus (Liu et al., 2002).
PGE2 was reported to induce the accumulation of IL-8 mRNA
and protein production in human colonic epithelial cells (Yu
and Chadee, 1998). PGE2 induces IL-8 mRNA transcription
through PGE2 receptor 1- and 4-dependent signal transduc-
tion pathway in human T cells (Caristi et al., 2005). IL-8 is
well known for its angiogenesis capability in many human
cancers. Our study revealed that there are slight increases in
IL-8 mRNA levels in COX-2-overexpressing clones (varying
from 1.1- to 1.6-fold), whereas VEGF-A showed a more
prominent increase in mRNA (1.8- to 2.4-fold). Secreted
bFGF was also increased markedly in COX-2-overexpressing
clones, by ELISA. Therefore, in addition to VEGF-A and bFGF,
the role of IL-8 in mediating angiogenesis in COX-2-
overexpressing BCC is worthy of further investigation.
Several apoptosis regulators were examined in our study.
Mcl-1 and Bcl-2, both members of Bcl-2 family, were
significantly upregulated in COX-2-overexpressing BCC cells,
whereas other Bcl-2 members were not. This implicates Mcl-
1 and Bcl-2 in COX-2-mediated antiapoptotic effects. Over-
expression of COX-2 on rat intestinal epithelial cells results in
inhibition of apoptosis and overexpression of Bcl-2 (Tsujii
and DuBois, 1995). Exposure of a variety of cancer cells to a
selective COX-2 inhibitor induces apoptosis (Arico et al.,
2002; Elder et al., 2002). One potential mechanism for the
proapoptotic activity of COX-2 inhibitors is the downregula-
tion of Bcl-2 (Sheng et al., 1998). Tumor tissue expressed
reduced levels of proapoptotic proteins Bax and Bcl-XL, and
increased levels of the antiapoptotic protein Bcl-2 in COX-2
transgenic mice model. Decreased apoptosis of mammary
epithelial cells contributes to tumorigenesis in COX-2-over-
expressing transgenic mice (Liu et al., 2001).
The Mcl-1 gene was originally identified as an early gene
that is induced during differentiation of ML-1 myeloid
leukemia cells (Kozopas et al., 1993). Overexpression of
Mcl-1 delays apoptosis via a broad array of agents, such as
c-Myc overexpression, growth factor withdrawal, and other
cytotoxic agents (Ando et al., 1998; Chao et al., 1998; Wang
et al., 1999). The intracellular distribution of Mcl-1 protein
overlaps with that of Bcl-2 protein, with prominent mito-
chondrial membrane localization (Yang et al., 1995).
Previously, we demonstrated that Mcl-1 upregulation is
involved in IL-6-mediated antiapoptotic effects. Recently,
Mcl-1 expression has been shown to be upregulated by COX-
2/PGE2 in lung adenocarcinoma cell line (Lin et al., 2001).
Increased levels of Mcl-1 induced by the overexpression of
COX-2 were reported in cholangiocarcinoma and lympho-
mas (Nzeako et al., 2002; Wun et al., 2004).
COX-2 is present in normal skin, benign epidermal
proliferation, and malignant skin neoplasm (Buckman et al.,
1998; Kagoura et al., 2001). Sun exposure is the essential
causal factor of BCC. Acute exposure of human keratinocytes
to UVB irradiation results in increased production of PGE2
and increased expression of COX-2 (Buckman et al., 1998).
COX-2 protein expression is upregulated in the human
epidermis after exposure to UVB (Buckman et al., 1998).
Chronic inflammation upregulates mediators of inflammatory
response, such as COX-2, leading to the production of
inflammatory cytokines and prostaglandins, which may
suppress cell-mediated immune response and promote
angiogenesis (O’Byrne and Dalgleish, 2001). Topical appli-
cation of celecoxib also inhibits chronic inflammation and
UVB-induced papilloma/carcinoma in Skh/hr mice (Wilgus
et al., 2003). Recently, COX-2 was reported as a target of
treatment in conjunction with photodynamic therapy in many
skin cancers (Akita et al., 2004). Combination of 5-fluoro-
uracil and celecoxib also displayed synergistic regression
of UVB-induced skin tumors (Wilgus et al., 2004). Our
data showed that tumor aggressiveness, defined as
a higher microvessel density and deeper local invasion
depth, was associated with levels of COX-2 expression
(manuscript in preparation). COX-2 thus might serve as a
chemopreventive and therapeutic target in human skin
cancers.
Finally, the present study reveals that COX-2 induces
antiapoptotic activity and angiogenesis in BCC by upregula-
tion of Bcl-2 and Mcl-1, as well as secreted VEGF-A and
bFGF. The exact molecular mechanism and downstream
effectors that mediate angiogenesis and tumorigenesis in
COX-2-overexpressing cell line remain to be elucidated by a
further genome-wide analysis. Our findings suggest that
blocking COX-2 function may increase susceptibility to
apoptosis and inhibit angiogenesis in BCC, thus providing a
feasible scheme for treatment and prevention of human BCC.
Further clinical trials may be needed to test the effectiveness
of COX-2-specific inhibitor combined with chemotherapeu-
tic agents or photodynamic therapy in the treatment of
human BCC. COX-2 inhibition might have beneficial effects,
especially for BCC with a higher level of COX-2 expression or
aggressive phenotypes. We hope to find more specific
therapeutic targets that can be useful in treatment of human
BCC in the near future.
1148 Journal of Investigative Dermatology (2006), Volume 126
J-W Tjiu et al.
Effect of COX-2 Overexpression in BCC Cell Line
MATERIALS AND METHODS
The medical ethical committee of the National Taiwan University
College of Medicine approved all described studies. The study was
conducted according to the Declaration of Helsinki Principles.
Cell origin, cell culture, and establishment of COX-2
transfectants
The human BCC cell line (parental BCC cells, originally designated
BCC-KMC-1) originated from an undifferentiated BCC derived from
a trauma scar. The 130–135th passages of this cell line were used in
this study. The pCMV-COX-2, a constitutive expression vector,
carries full-length human COX-2 cDNA under the control of the
cytomegalovirus promoter/enhancer sequence and with a neomycin
selection marker. The BCC cells were transfected with pCMV-COX-2
or control pcDNA3 vector (GIBCO Invitrogen Co., Grand Island,
NY), containing a cytomegalovirus promoter and a neomycin
selection marker, using the TransFastTM transfection reagent (Pro-
mega Co., Madison, WI). After 24 hours, cells were replanted in
RPMI 1640 medium (GibcoBRL, Rockville, MD) with 10% fetal calf
serum and 500 ng/ml G418 (Sigma Chemical Co., St Louis, MO). The
G418-resistant clones were selected and expanded. For this study,
we used high-expression transfectants (B4, C5, E4, and G7), the
parental BCC cells and BCC cells transfected with control vector
(pcDNA) served as controls. All of these cells were grown at 371C
and 5% CO2 in RPMI 1640 medium supplemented with 10% (vol/
vol) fetal bovine serum.
Antibodies and reagents
Anti-Mcl-1 (BD Pharmingen, San Diego, CA), anti-Bcl-2 (BD
Pharmingen), anti-Bcl-XL (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-BAD (Santa Cruz Biotechnology), anti-VEGF-A (R&D
Systems, Minneapolis, MN), anti-COX-2 (Cayman Chemical, Ann
Arbor, MI), and anti-a-tubulin antibody (NeoMarkers, Freemont, CA)
were used in immunoblotting analysis. Neutralizing antibody (goat
polyclonal anti-bFGF antibody) was obtained from R&D Systems.
The NS-398, a COX-2-specific inhibitor, was obtained from Cayman
Chemical (Ann Arbor, MI).
Apoptosis ELISA assay
A sensitive ELISA that detects cytoplasmic histone-associated DNA
fragments was performed, according to the manufacturer’s protocol
(Cell Death Detection ELISAPLUS; Roche Diagnostic GmbH,
Mannheim, Germany). Briefly, human BCC cell lines were cultured
in 6 cm Petri dishes (106 cells/dish) overnight, then treated with UVB
25 mJ/cm2 and harvested at 6 and 12 hours. An amount of 1 104
cells was then centrifuged at 200 g. The cells were lysed with lysis
buffer for 30 minutes, followed by centrifugation at 200 g for
10 minutes at room temperature. The supernatant was collected and
incubated with immunoreagent for 2 hours. After washing, a
substrate solution was added into each well and kept in the dark
until the color developed. The reaction was determined in a
spectrophotometry at 405 nm, with 490 nm as the reference
wavelength. The result was presented as enrichment factor (EF).
The EF is defined as mU of sample/mU of the corresponding negative
control (mU¼ absorbance (103)).
Flow cytometry analysis
The BCC/COX-2 cells and vector controls (1 106) were treated with
UVB 25 mJ/cm2. At an indicated time, cells were harvested and fixed
in 75% methanol at 201C for at least 30 minutes. After centrifuga-
tion (100 g) for 5 minutes at 41C, the cell pellets were resuspended
in 1 ml of phosphate-buffered saline (PBS) containing 2 mg/ml RNase
A and incubated for 30 minutes. Finally, propidium iodide solution
was added to a final concentration of 40 mg/ml. Fluorescence
emitted from the PI-DNA complex was quantified after laser
excitation of the fluorescent dye using FACS flow cytometry
(Becton-Dickinson, Labware, Bedford, MA).
Preparation of CM
Parental BCC, pcDNA, B4, or G7 cells were plated in 1 ml of
culture medium at 2 105 cells/well in 24-well 18 mm culture
dishes. After serum starvation for 1 day, the culture supernatants
were collected 24 hours later and centrifuged sequentially at
12,500 g with Microcon YM-3 centrifugal filter devices (Millipore
Co., Bedford, MA) (with the cutoff of molecules smaller than
3,000 Da) for 30 minutes to obtain a 10-fold concentrate culture
supernatant.
Matrigel blood plug in vivo assay
Matrigel blood plug assay was performed as described
previously (Plunkett and Hailey, 1990; O’Reilly et al., 1997). Briefly,
C57BL6j mice (five per group) were each injected subcutaneously
with 50 ml of CM from various cell lines mixed with 450 ml
Matrigel (growth factor reduced) (Becton-Dickinson, Labware,
Bedford, MA) and 40 U heparin/ml at 41C. Mice were killed 6 days
later; gels were recovered and processed for further studies.
Neovessels was quantified by Drabkin method, measuring
hemoglobin of the plug with the Drabkin reagent kit 525 (Sigma,
St Louis, MI).
In vitro capillary tube formation on Matrigel
Human umbilical vein was collected with consent. The HUVEC
capillary tube formation was evaluated as follows. Twenty-four-well
18 mm tissue culture dishes were coated with Matrigel basement
membrane matrix (300 ml/well) (Becton-Dickinson) at 41C and
allowed to polymerize at 371C for at least 30 minutes. The HUVECs
(5 104 cells/well, in 24-well 18 mm tissue culture dishes) were
grown in a final volume of 0.4 ml culture medium containing 150 ml
M199 (GibcoBRL, Rockville, MD) and 250 ml CM. After 6 hours
incubation, tube formation was observed through an inverted,
phase-contrast photomicroscope, then photographed and counted.
The number of tube formations was measured by counting the
number of tube-like structures formed by connected endothelial cells
in five randomly selected 9.7 mm2 microscopic fields. The assay was
performed in triplicate.
COX-2-specific RNA interference
The target sequence for the COX-2 siRNA was bases 291–313 of
NM000963.1 (50-aactgctcaacaccggaattttt-30) following the descrip-
tion by Denkert et al. (2003). The pRNA-U6/neo (GenScript Corp.,
Piscataway, NJ) is an siRNA expression vector with neomycin as the
selection marker. We constructed pRNA-U6/COX-2, a constitutively
expressed vector, which carries the COX-2 siRNA sequence under
the control of U6 promoter. The BCC/COX-2 cells were transiently
transfected with pRNA-U6/COX-2 overnight. Inhibition of COX-2
protein was confirmed by Western blotting and function inhibition
was measured by the PGE2 EIA kit.
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Reverse transcriptase-PCR
The RNAs from BCC/COX-2 and vector control were isolated using
Trizol followed by chloroform. The mixture was then centrifuged,
which yielded an upper aqueous phase containing total RNA. After
precipitation with isopropanol, the RNA pellet was redissolved in
denaturing solution, reprecipitated with isopropanol, and washed
with 75% ethanol. An amount of 5mg of total RNA was subjected to
first-strand synthesis using Random Hexamer (Promega, Madison,
WI) and M-MLV Reverse Transcriptase (RNase H Minus) (Promega,
Madison, WI) at 371C for 3 hours. The cDNA was then diluted to a
final volume of 20 ml and quantified. Each 1ml PCR reaction
contained Taq polymerase (0.5 U/l; Protech Technology, Taipei,
Taiwan) and 25 pmol each of the sense and the antisense primers in
PCR buffer (10 mM Tris pH 9, 50 mM KCl, 6 mM MgCl2, 0.01%
gelatin, and 0.1% Triton X-100). Primer sequences are as follows: IL-
8: sense 50-CTC TCT TGG CAG CCT TCC TGA TT-30 and antisense
50-AAC TTC TCC ACA ACC CTC TGC AC-30; VEGF-A: sense 50-AGC
TAC TGC CAT CCA ATC GC-30 and antisense 50-GGG CGA ATC
CAA TTC CAA GAG-30; platelet-derived growth factor: sense 50-
AAG CAT GTG CCG GAG AAG CG-30 and antisense 50-TCC TCT
AAC CTC ACC TGG AC-30; bFGF: sense 50-AGT CTC CTG GAG
AAA GCT-30 and antisense 50-CCC TTG ATG GAC ACA ACT-30; and
b-actin: sense 50-CGT CTG GAC CTG GCT GGC CGG GAC C-30
and antisense 50-CTA GAA GCA TTT GCG GTG GAC GAT G-30. The
reaction mixture was incubated for 5 minutes at 941C and then
amplified by 25 PCR cycles (denaturing for 1 minute at 941C,
annealing for 1 minute at 561C, and extending for 1 minute at 721C).
Each PCR product was then analyzed on a 2% agarose gel stained
with 1mg/ml ethidium bromide and photographed (Syngene;
Syngene Bio Imaging System). Intensity of bands on the photographs
was quantified by scanning laser densitometry.
Enzyme immunoassay (ELISA)
The PGE2 EIA kit (Cayman Chemical, Ann Arbor, MI) and bFGF and
VEGF ELISA kits (R&D Systems) were used to determine the respective
levels of PGE2, bFGF, and VEGF in cell culture supernatants. Each
measurement was carried out according to the manufacturer’s
instructions, and each experiment was repeated in triplicate.
Western blot analysis
Cell lysates were prepared as described previously (Kuo et al., 1998).
A 50 mg sample of each lysate was subjected to electrophoresis on a
10% SDS-polyacrylamide gel for detection of Mcl-1, Bcl-2, Bax, Bcl-
x/L, VEGF-A, and COX-2. The samples were then electroblotted onto
nitrocellulose paper. After blocking, blots were incubated with anti-
Mcl-1, anti-Bcl-2, anti-Bax, anti-Bcl-x/L, anti-VEGF, and anti-Cox-2
antibodies in PBS containing Triton X-100 (PBST) for 1 hour followed
by two washes (15 minutes each) in PBST. The samples were then
incubated with horseradish peroxidase-conjugated goat anti-mouse
IgG for 30 minutes. After washing, blots were incubated for 1 minute
with the Western blotting reagent ECL (Amersham Biosciences UK
Limited, Buckinghamshire, England) and chemiluminescence was
detected by exposing the filters to Kodak-X-Omat films for
30 seconds to 3 minutes.
Colony growth in soft agar
Growth in soft agar was determined in six-well 35 mm diameter
dishes prepared with a lower layer of 0.7% agar solution in RPMI
with 10% fetal bovine serum, then overlaid with a 0.35% agar
solution, also in growth medium, in which 1 106 cells were
resuspended. Colonies were scored 28 days after preparation. (The
colonies larger than 0.1 mm in diameter were scored as positive.)
The pcDNA (vector control), B4, and G7 (COX-2-overexpressing
clones) were subjected for colony formation assays.
Tumorigenicity assay in SCID mice. The SCID mice purchased
from Tzu-Chi University Animal Center in Taiwan were housed in a
dedicated SCID mouse facility with microisolator caging. The mice
were handled under a unidirectional laminar airflow hood. Control-
transfected BCC cells (pcDNA) and COX-2-transfected BCC cells (B4
and G7 clones) were trypsinized, washed with PBS, resuspended in
PBS, and adjusted to a concentration of 5 106 cells/100 ml in PBS.
The cell suspensions were then mixed with an equal volume of
Matrigel before subcutaneous injection into SCID mice. Tumor
development was followed in individual animals (four per group) by
weekly sequential caliper measurements of length (L), width (W),
and depth (H). Tumor volume was calculated by the formula
LWH 0.5236. After 7 weeks, the mice were killed; the tumors
were removed and weighed. A segment of the tumor was excised
and fixed either in OCT embedding medium (Sakura Finetek USA
Inc., Torrance, CA) or 10% neutral buffered formalin.
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